Cited 2 times in
Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이상훈 | - |
dc.contributor.author | 장윤수 | - |
dc.date.accessioned | 2022-11-24T00:50:38Z | - |
dc.date.available | 2022-11-24T00:50:38Z | - |
dc.date.issued | 2021-03 | - |
dc.identifier.issn | 1759-7706 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191028 | - |
dc.description.abstract | Background: In this study, we investigated the risk factors of acquired T790M mutation among patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) tyrosine mutation who were treated with EGFR-tyrosine kinase inhibitors (TKIs). The aim was to identify the clinical impact of rebiopsy. Methods: This multicenter, retrospective cohort study was conducted in South Korea from January 2007 to June 2017. Patients with adenocarcinoma with EGFR mutation who underwent rebiopsy and were treated with EGFR-TKIs were included. Results: Of a total of 352 patients, T790M mutation was identified in 156 (41.9%) at the time of rebiopsy. The median duration from initial biopsy to rebiopsy was 17 months. Univariate logistic regression analysis revealed associations of exon 19 deletion (odds ratio [OR], 1.643; p = 0.026), absence of L858R (OR, 0.627; p = 0.042), and previous EGFR-TKI treatment duration (OR, 1.039; p < 0.001) with T790M mutation. Previous EGFR-TKI treatment duration (OR, 3.580; p < 0.001) was independently associated with T790M mutation. A multivariate Cox proportional hazard model revealed that brain metastasis at initial diagnosis (hazard ratio, 1.390; p = 0.050) tended to be associated with T790M mutation. Among the patients with T790M mutation at rebiopsy, the osimertinib user group (n = 90) had a better one-year survival (68.7 vs. 58.3%, p = 0.048) than the osimertinib nonuser group (n = 66). Conclusions: Rebiopsy might affect the clinical course of patients with EGFR-mutant adenocarcinoma who receive EGFR-TKIs. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Wiley Publishing Asia Pty Ltd ; Tianjin Lung Cancer Institute | - |
dc.relation.isPartOf | THORACIC CANCER | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adenocarcinoma of Lung / surgery* | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biopsy / methods* | - |
dc.subject.MESH | ErbB Receptors / adverse effects | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms / surgery* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yunha Nam | - |
dc.contributor.googleauthor | Ho Cheol Kim | - |
dc.contributor.googleauthor | Young-Chul Kim | - |
dc.contributor.googleauthor | Seung Hun Jang | - |
dc.contributor.googleauthor | Kye Young Lee | - |
dc.contributor.googleauthor | Shin Yup Lee | - |
dc.contributor.googleauthor | Sang Hoon Lee | - |
dc.contributor.googleauthor | Sung Yong Lee | - |
dc.contributor.googleauthor | Seong Hoon Yoon | - |
dc.contributor.googleauthor | Jeong-Seon Ryu | - |
dc.contributor.googleauthor | Tae Won Jang | - |
dc.contributor.googleauthor | Yoon Soo Chang | - |
dc.contributor.googleauthor | Seung Joon Kim | - |
dc.contributor.googleauthor | Chan Kwon Park | - |
dc.contributor.googleauthor | Jeong Eun Lee | - |
dc.contributor.googleauthor | Chi Young Jung | - |
dc.contributor.googleauthor | Chang-Min Choi | - |
dc.identifier.doi | 10.1111/1759-7714.13857 | - |
dc.contributor.localId | A02836 | - |
dc.contributor.localId | A03456 | - |
dc.relation.journalcode | J02725 | - |
dc.identifier.eissn | 1759-7714 | - |
dc.identifier.pmid | 33529490 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/1759-7714.13857 | - |
dc.subject.keyword | EGFR-TKI | - |
dc.subject.keyword | T790M | - |
dc.subject.keyword | acquired resistance | - |
dc.subject.keyword | lung cancer | - |
dc.subject.keyword | rebiopsy | - |
dc.contributor.alternativeName | Lee, Sang Hoon | - |
dc.contributor.affiliatedAuthor | 이상훈 | - |
dc.contributor.affiliatedAuthor | 장윤수 | - |
dc.citation.volume | 12 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 890 | - |
dc.citation.endPage | 898 | - |
dc.identifier.bibliographicCitation | THORACIC CANCER, Vol.12(6) : 890-898, 2021-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.